Formulary guidance and transparency from P&T to point of care


Reality Check on Migraine Prevention

Market access for migraine prevention treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 58% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In February 2020, the FDA approved H. Lundbeck A/S’s Vyepti (eptinezumab-jjmr) for the preventive treatment of migraine in adults. The recommended dose is 100 mg every three months. Vyepti is the first FDA-approved intravenous treatment for migraine prevention, according to the company’s news release
  • Key Findings: Payers have equal amount of power and position when it comes to coverage of prophylactic treatments of migraine. More than 90% require patients to fall under certain criteria for coverage eligibility

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.